Your browser doesn't support javascript.
loading
Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies.
Bose, Prithviraj; Perkins, Edward B; Honeycut, Connie; Wellons, Martha D; Stefan, Tammy; Jacobberger, James W; Kontopodis, Emmanouil; Beumer, Jan H; Egorin, Merrill J; Imamura, Chiyo K; Douglas Figg, W; Karp, Judith E; Koc, Omer N; Cooper, Brenda W; Luger, Selina M; Colevas, A Dimitrios; Roberts, John D; Grant, Steven.
Affiliation
  • Bose P; Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.
Cancer Chemother Pharmacol ; 69(6): 1657-67, 2012 Jun.
Article in En | MEDLINE | ID: mdl-22349810
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Protein-Tyrosine Kinases / Leukemia / Antineoplastic Combined Chemotherapy Protocols / Fusion Proteins, bcr-abl / Cyclin-Dependent Kinases / Protein Kinase Inhibitors Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Cancer Chemother Pharmacol Year: 2012 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Protein-Tyrosine Kinases / Leukemia / Antineoplastic Combined Chemotherapy Protocols / Fusion Proteins, bcr-abl / Cyclin-Dependent Kinases / Protein Kinase Inhibitors Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Cancer Chemother Pharmacol Year: 2012 Document type: Article Affiliation country: Country of publication: